Specialties

General

PBS funding recommended for dual combination therapy for PAH

By Michael Woodhead

18 Jan 2019

Share:

The PBS has signalled a move to subsidise dual combination therapy for patients with pulmonary arterial hypertension (PAH). A recommendation to subsidise combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE-5) inhibitor for patients with WHO Functional Class III and IV PAH was accepted by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November ...

Already a member?

Enter your email to keep reading.

OR

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.